Kanshas™ Drug Coated Balloon has been developed by Terumo using a unique coating technology to address some limitations of first generation DCBs and to offer solutions for your fem-pop treatment.1
The Kanshas™ DCB is indicated for percutaneous transluminal angioplasty (PTA) in patients with obstructive disease of peripheral arteries.
Please contact our sales representative for ordering information.
2 Data on file at MicroVention FD15-0005
3 Kanshas DCB data on file at MicroVention, TR-15-159, animal study report, n=40. The other products' data were derived from literature and presentations as below. The end points of the studies from the other products were 30 and 45 days respectively.
Saami K. et al. "Vascular, Downstream, and Pharmacokinetic Responses to Treatment with a Low Dose Drug-Coated Balloon in a Swine Femoral Artery Model". Catheterization and Cardiovascular Interventions83:132-140(2014).
Robert J. Melder et al. "IN.PACTDEB technology and Pre-clinical Science". Presented at Leipzig Interventional Course(2013).
Carlos A. Gongora, et al. "Impact of Paclitaxel Dose on Tissue Pharmacokinetics and Vascular Healing". JACC CardiovascularInterventions; 8(8):1115-23(2015).
Dorothea I. Axel, et al. "Paclitaxel Inhibits Arterial Smooth Muscle Cell Proliferation and Migration In Vitro and In Vivo Using Local Drug Delivery". Circulation. 1997;96:636-645
4 Data on file at MicroVention FD15-0005